Cargando…

Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells

Here, we developed Pluronic(®) P123/F127 (poloxamer) mixed micelles for the intravenous delivery of the anticancer drug sorafenib (SRB) or its combination with verteporfin (VP), a photosensitizer for photodynamic therapy that should complement well the cytotoxicity profile of the chemotherapeutic. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellosi, Diogo Silva, Moret, Francesca, Fraix, Aurore, Marino, Nino, Maiolino, Sara, Gaio, Elisa, Hioka, Noboru, Reddi, Elena, Sortino, Salvatore, Quaglia, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019320/
https://www.ncbi.nlm.nih.gov/pubmed/27660441
http://dx.doi.org/10.2147/IJN.S103344
_version_ 1782453036574048256
author Pellosi, Diogo Silva
Moret, Francesca
Fraix, Aurore
Marino, Nino
Maiolino, Sara
Gaio, Elisa
Hioka, Noboru
Reddi, Elena
Sortino, Salvatore
Quaglia, Fabiana
author_facet Pellosi, Diogo Silva
Moret, Francesca
Fraix, Aurore
Marino, Nino
Maiolino, Sara
Gaio, Elisa
Hioka, Noboru
Reddi, Elena
Sortino, Salvatore
Quaglia, Fabiana
author_sort Pellosi, Diogo Silva
collection PubMed
description Here, we developed Pluronic(®) P123/F127 (poloxamer) mixed micelles for the intravenous delivery of the anticancer drug sorafenib (SRB) or its combination with verteporfin (VP), a photosensitizer for photodynamic therapy that should complement well the cytotoxicity profile of the chemotherapeutic. SRB loading inside the core of micelles was governed by the drug:poloxamer weight ratio, while in the case of the SRB–VP combination, a mutual interference between the two drugs occurred and only specific ratios could ensure maximum loading efficiency. Coentrapment of SRB did not alter the photophysical properties of VP, confirming that SRB did not participate in any bimolecular process with the photosensitizer. Fluorescence resonance energy-transfer measurement of micelles in serum protein-containing cell-culture medium demonstrated the excellent stability of the system in physiologically relevant conditions. These results were in line with the results of the release study showing a release rate of both drugs in the presence of proteins slower than in phosphate buffer. SRB release was sustained, while VP remained substantially entrapped in the micelle core. Cytotoxicity studies in MDA-MB231 cells revealed that at 24 hours, SRB-loaded micelles were more active than free SRB only at very low SRB concentrations, while at 24+24 hours a prolonged cytotoxic effect of SRB-loaded micelles was observed, very likely mediated by the block in the S phase of the cell cycle. The combination of SRB with VP under light exposure was less cytotoxic than both the free combination and VP-loaded micelles + SRB-loaded micelles combination. This behavior was clearly explainable in terms of micelle uptake and intracellular localization. Besides the clear advantage of delivering SRB in poloxamer micelles, our results provide a clear example that each photochemotherapeutic combination needs detailed investigations on their particular interaction, and no generalization on enhanced cytotoxic effects should be derived a priori.
format Online
Article
Text
id pubmed-5019320
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50193202016-09-22 Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells Pellosi, Diogo Silva Moret, Francesca Fraix, Aurore Marino, Nino Maiolino, Sara Gaio, Elisa Hioka, Noboru Reddi, Elena Sortino, Salvatore Quaglia, Fabiana Int J Nanomedicine Original Research Here, we developed Pluronic(®) P123/F127 (poloxamer) mixed micelles for the intravenous delivery of the anticancer drug sorafenib (SRB) or its combination with verteporfin (VP), a photosensitizer for photodynamic therapy that should complement well the cytotoxicity profile of the chemotherapeutic. SRB loading inside the core of micelles was governed by the drug:poloxamer weight ratio, while in the case of the SRB–VP combination, a mutual interference between the two drugs occurred and only specific ratios could ensure maximum loading efficiency. Coentrapment of SRB did not alter the photophysical properties of VP, confirming that SRB did not participate in any bimolecular process with the photosensitizer. Fluorescence resonance energy-transfer measurement of micelles in serum protein-containing cell-culture medium demonstrated the excellent stability of the system in physiologically relevant conditions. These results were in line with the results of the release study showing a release rate of both drugs in the presence of proteins slower than in phosphate buffer. SRB release was sustained, while VP remained substantially entrapped in the micelle core. Cytotoxicity studies in MDA-MB231 cells revealed that at 24 hours, SRB-loaded micelles were more active than free SRB only at very low SRB concentrations, while at 24+24 hours a prolonged cytotoxic effect of SRB-loaded micelles was observed, very likely mediated by the block in the S phase of the cell cycle. The combination of SRB with VP under light exposure was less cytotoxic than both the free combination and VP-loaded micelles + SRB-loaded micelles combination. This behavior was clearly explainable in terms of micelle uptake and intracellular localization. Besides the clear advantage of delivering SRB in poloxamer micelles, our results provide a clear example that each photochemotherapeutic combination needs detailed investigations on their particular interaction, and no generalization on enhanced cytotoxic effects should be derived a priori. Dove Medical Press 2016-09-06 /pmc/articles/PMC5019320/ /pubmed/27660441 http://dx.doi.org/10.2147/IJN.S103344 Text en © 2016 Pellosi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Pellosi, Diogo Silva
Moret, Francesca
Fraix, Aurore
Marino, Nino
Maiolino, Sara
Gaio, Elisa
Hioka, Noboru
Reddi, Elena
Sortino, Salvatore
Quaglia, Fabiana
Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
title Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
title_full Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
title_fullStr Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
title_full_unstemmed Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
title_short Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
title_sort pluronic(®) p123/f127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019320/
https://www.ncbi.nlm.nih.gov/pubmed/27660441
http://dx.doi.org/10.2147/IJN.S103344
work_keys_str_mv AT pellosidiogosilva pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT moretfrancesca pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT fraixaurore pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT marinonino pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT maiolinosara pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT gaioelisa pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT hiokanoboru pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT reddielena pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT sortinosalvatore pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells
AT quagliafabiana pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells